NextCure (NXTC)
(Delayed Data from NSDQ)
$1.60 USD
-0.03 (-1.84%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $1.64 +0.04 (2.50%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NXTC 1.60 -0.03(-1.84%)
Will NXTC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NXTC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NXTC
Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing
NextCure (NXTC) Down on Shelving Plans to Develop Candidate
NXTC: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy
NextCure, Inc. (NXTC) Moves to Buy: Rationale Behind the Upgrade
Other News for NXTC
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
NextCure (NXTC) Gets a Buy from Piper Sandler
Buy Rating Affirmed on NextCure’s NC410 Promising Clinical Outcomes in MSS-CRC and Ovarian Cancer
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
NextCure presents Phase 1b data on NC410 and pembrolizumab combo at ASCO